Nigeria

Population 2018  196 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>429 (280–609)</td>
<td>219 (143–311)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>53 (34–75)</td>
<td>27 (17–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>21 (13–32)</td>
<td>11 (6.4–16)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>130 (73–190)</td>
<td>64 (37–98)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>32 (20–47)</td>
<td>16 (10–24)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 4.3% (3.2–5.5)
- Previously treated cases: 15% (11–19)

TB case notifications, 2018

- Total new and relapse: 103,921
- % tested with rapid diagnostics at time of diagnosis: 54%
- % with known HIV status: 100%
- % pulmonary: 96%
- % bacteriologically confirmedººº: 77%
- % children aged 0-14 years: 8%
- % women: 34%
- % men: 58%

Total cases notified: 106,533

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 24% (17–37)
- TB patients facing catastrophic total costs, 2017: 71% (68–73)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 38% (19–59)

TB/HIV care in new and relapse TB patients, 2018

- Patients with known HIV status who are HIV-positive: 12,700 (12%)
  - on antiretroviral therapy: 11,032 (87%)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº: 65%
  - New cases: 65%
  - Previously treated cases: 88%

Laboratory-confirmed cases*

- MDR/RR-TB: 2,275, XDR-TB: 31

Patients started on treatment**

- MDR/RR-TB: 1,895, XDR-TB: 14

MDR/RR-TB cases tested for resistance to second-line drugs

- Total: 1,895

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 101,734 (86%)
- Previously treated cases, excluding relapse, registered in 2017: 2,781 (82%)
- HIV-positive TB cases registered in 2017: 13,851 (76%)
- MDR/RR-TB cases started on second-line treatment in 2016: 1,251 (77%)
- XDR-TB cases started on second-line treatment in 2016: 1,251 (77%)

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 62%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 19% (17–21)

TB financing, 2019

- National TB budget (US$ millions): 278
  - Funding source: 8% domestic, 32% international, 60% unfunded

---

* Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº MDR/RR-TB: Tested for resistance to rifampicin and/or isoniazid
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-11-15
Data: www.who.int/tb/data